Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Valdecoxib is a non-steroidal anti-inflammatory drug that selectively inhibits COX-2, exhibiting IC50 values of 26.1 and 0.87 µM for COX-1 and COX-2, respectively, in a human whole blood assay. The COX-2 selectivity ratio of 30 for valdecoxib in this assay is similar to the ratio of 35 observed for rofecoxib . COX-2 selective inhibitors, including this compound, have been implicated as risk factors in acute atherothrombotic events.
Valdecoxib is supplied as a crystalline solid. A stock solution may be made by dissolving the valdecoxib in an organic solvent purged with an inert gas. Valdecoxib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of valdecoxib in these solvents is 5 mg/ml in ethanol and 20 mg/ml in DMSO and DMF. Valdecoxib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, valdecoxib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Valdecoxib has a solubility of 0.5 mg/ml in a 1:8 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Mardini, I.A. and Fitzgerald, G.A. Selective inhibitors of cyclooxygenase-2: A growing class of antiinflammatory drugs. Mol. Interv. 1, 30-38 (2001).
Walter, M.F., Jacob, R.F., Day, C.A., et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: Comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177, 235-243 (2004).
Zhang, J., Ding, E.L., and Song, Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials. JAMA 296(13), 1619-1632 (2006).